Key result
Ketorolac significantly prolonged bleeding time and inhibited platelet aggregation, with no interaction found between ketorolac and heparin.
Why the study?
Does ketorolac, alone or in combination with low dose heparin, affect haemostasis in healthy male volunteers?
Population
12 healthy male volunteers
Comparison
Ketorolac alone or in combination with low dose… vs Placebo alone or heparin alone
Design
RCT, double blind, placebo controlled
Authors
Loading...
Supports cautious ketorolac use in bleeding-risk patients despite no heparin interaction; extends RCT evidence on haemostatic effects in volunteers.
RCT (n=12)
Double-blind
Does ketorolac, alone or in combination with low dose heparin, affect haemostasis in healthy male volunteers?
Ketorolac alters platelet function and bleeding time without interacting with the anticoagulant effects of low-dose heparin, suggesting it can be co-administered but requires caution in patients with bleeding risks.
Spowart et al. (1988) conducted an RCT in Healthy volunteers (n=12). Ketorolac alone and in combination with low dose heparin vs. Placebo was evaluated on Haemostasis (bleeding time, platelet aggregation, thromboxane production, kaolin cephalin clotting time, anti-Xa levels). Ketorolac significantly prolonged bleeding time and inhibited platelet aggregation, with no interaction found between ketorolac and heparin.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: